Indivior PLC (NASDAQ:INDV) Short Interest Up 9.9% in December

Indivior PLC (NASDAQ:INDV) saw a large increase in short interest in December. As of December 31st, there was short interest totalling 1,220,000 shares, an increase of 9.9% from the December 15th total of 1,110,000 shares. Approximately 1.1% of the shares of the stock are short sold. Based on an average daily volume of 1,280,000 shares, the short-interest ratio is presently 1.0 days.

Institutional Trading of Indivior

Hedge funds have recently modified their holdings of the company. Stifel Financial Corp purchased a new position in Indivior during the third quarter worth $100,000. Bank of New York Mellon Corp bought a new stake in shares of Indivior in the 2nd quarter worth about $188,000. Melqart Asset Management UK Ltd bought a new stake in shares of Indivior in the 3rd quarter worth about $132,000. XTX Topco Ltd bought a new stake in shares of Indivior in the 2nd quarter worth about $249,000. Finally, Jane Street Group LLC bought a new stake in shares of Indivior in the 3rd quarter worth about $180,000. 60.33% of the stock is owned by hedge funds and other institutional investors.

Indivior Stock Performance

Shares of INDV traded down $0.01 during mid-day trading on Friday, hitting $11.65. 1,060,388 shares of the stock were exchanged, compared to its average volume of 974,047. The company has a market cap of $1.61 billion, a PE ratio of -291.18 and a beta of 0.74. Indivior has a 52-week low of $7.33 and a 52-week high of $23.22. The firm has a 50-day moving average of $11.46 and a two-hundred day moving average of $11.07.

Indivior (NASDAQ:INDV) last issued its quarterly earnings data on Thursday, October 24th. The company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.15. The business had revenue of $307.00 million for the quarter, compared to analysts’ expectations of $302.25 million. Indivior had a negative return on equity of 351.08% and a negative net margin of 0.17%. On average, sell-side analysts predict that Indivior will post 1.62 EPS for the current year.

Analyst Ratings Changes

INDV has been the topic of a number of research analyst reports. Piper Sandler reissued an “overweight” rating and issued a $16.00 price target (up from $15.00) on shares of Indivior in a report on Friday, October 25th. Craig Hallum lowered their price target on Indivior from $20.00 to $16.00 and set a “buy” rating on the stock in a report on Friday, October 11th.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.